Physician profile
David A Nover
NPI 1922046861
$47,015.21
in general payments reported to CMS, 2019-2025
28 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $668 · 2021: $826 · 2022: $979 · 2023: $11K · 2024: $18K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Honoraria: $12K · Food and Beverage: $4,946 · Travel and Lodging: $3,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,750.00 |
| Honoraria | $11,825.00 |
| Food and Beverage | $4,946.42 |
| Travel and Lodging | $3,000.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $40,435.20 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,207.54 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $865.32 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $759.94 | 2019-2022 | |
| Abbvie INC. | $601.43 | 2021-2025 | |
| Alkermes, INC. | $549.27 | 2021-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $465.15 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $385.97 | 2019-2025 | Trintellix |
| Allergan, INC. | $365.06 | 2019-2020 | |
| Corium, LLC | $205.20 | 2022-2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $175.12 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $140.82 | 2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $133.50 | 2019 | |
| Vanda Pharmaceuticals INC. | $133.32 | 2019-2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $112.46 | 2025 | Jornay Pm |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $109.57 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $80.37 | 2021-2024 | |
| Tris Pharma INC | $60.74 | 2024-2025 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $47.93 | 2019-2020 | |
| Shire North American Group INC | $33.39 | 2019 | |
| Neuronetics, INC. | $31.35 | 2023 | Neurostar Tms Therapy System |
| Neurocrine Biosciences, INC. | $19.87 | 2024 | Ingrezza |
| Almatica Pharma LLC | $19.21 | 2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $18.37 | 2024 | Quviviq |
| Vertical Pharmaceuticals, LLC | $16.47 | 2025 | Relexxii |
| Merck Sharp & Dohme LLC | $15.88 | 2023 | Belsomra |
| Bausch Health US, LLC | $15.19 | 2019 | |
| Sumitomo Pharma America, INC. | $11.57 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.